The career development plan described in the present proposal will allow the applicant to develop and expand his research career into new areas of investigation that complement current areas of expertise. The applicant has extensive training and experience in behavioral neuropharmacology and substance abuse with primary expertise in the neuropharmacology of CNS stimulants. The proposed development of in vivo microdialysis techniques in conscious monkeys trained to self-administer cocaine and related stimulants will allow for the determination of neurochemical changes associated with the behavioral and reinforcing properties of abused stimulants. The capacity to study neurochemistry directly during ongoing behavioral experiments will be a major advancement in the research career of the applicant. In addition, the development of positron emission tomography (PET) imaging techniques in conscious monkeys will expand further the applicant's ability to characterize and quantify the CNS effects of abused stimulants. A major focus of the research plan will involve the pharmacological manipulation of monoamine systems to assess potential changes in sensitivity to the CNS effects of cocaine. The studies proposed will provide an innovative pre-clinical model to identify useful pharmacotherapies for stimulant abuse. In addition to research activities, the applicant will commit effort to educational activities related to biomedical research and substance abuse. The host institution, Emory University, has a well-established program related to neuroscience and substance abuse research that is ideally suited to the career development plan. The University will provide the necessary resources and adequate time to ensure the development of the applicant as a productive, independent research scientist. The long-term commitment and support provided by an Independent Scientist Award will provide the opportunity to develop and integrate new skills and expertise into a unique multidisciplinary research program in substance abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Development Award - Research (K02)
Project #
5K02DA000517-04
Application #
6727651
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Aigner, Thomas G
Project Start
2001-03-01
Project End
2006-02-28
Budget Start
2004-03-01
Budget End
2005-02-28
Support Year
4
Fiscal Year
2004
Total Cost
$99,238
Indirect Cost
Name
Emory University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Felger, Jennifer C; Mun, Jiyoung; Kimmel, Heather L et al. (2013) Chronic interferon-? decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology 38:2179-87
McIntosh, Scot; Howell, Leonard; Hemby, Scott E (2013) Dopaminergic dysregulation in prefrontal cortex of rhesus monkeys following cocaine self-administration. Front Psychiatry 4:88
Sawyer, Eileen K; Mun, Jiyoung; Nye, Jonathon A et al. (2012) Neurobiological changes mediating the effects of chronic fluoxetine on cocaine use. Neuropsychopharmacology 37:1816-24
Kimmel, Heather L; Nye, Jonathon A; Voll, Ronald et al. (2012) Simultaneous measurement of extracellular dopamine and dopamine transporter occupancy by cocaine analogs in squirrel monkeys. Synapse 66:501-8
Manvich, Daniel F; Kimmel, Heather L; Cooper, Debra A et al. (2012) The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys. J Pharmacol Exp Ther 342:761-9
Murnane, Kevin Sean; Perrine, Shane Alan; Finton, Brendan James et al. (2012) Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry. Psychopharmacology (Berl) 220:495-508
Muly, E C; Votaw, J R; Ritchie, J et al. (2012) Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone. J Pharmacol Exp Ther 341:81-9
Bauzo, Rayna M; Kimmel, Heather L; Howell, Leonard L (2012) The cystine-glutamate transporter enhancer N-acetyl-L-cysteine attenuates cocaine-induced changes in striatal dopamine but not self-administration in squirrel monkeys. Pharmacol Biochem Behav 101:288-96
Andersen, Monica L; Sawyer, Eileen K; Carroll, F Ivy et al. (2012) Influence of chronic dopamine transporter inhibition by RTI-336 on motor behavior, sleep, and hormone levels in rhesus monkeys. Exp Clin Psychopharmacol 20:77-83
Murnane, K S; Kimmel, H L; Rice, K C et al. (2012) The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine (""ecstasy""): a concurrent microdialysis and plasma analysis study. Horm Behav 61:181-90

Showing the most recent 10 out of 35 publications